DBS: a UK (MHRA) regulatory perspective

被引：11

|

作者：

Beharry, Michelle ^{[1
]}

机构：

[1] UK MHRA, London SW8 5NQ, England

来源：

BIOANALYSIS | 2010年 / 2卷 / 08期

关键词：

D O I：

10.4155/BIO.10.109

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

收藏

页码：1363 / 1364

页数：2

相关论文

共 50 条

[11] UK MHRA suspends TGN 1412 trial
Reactions Weekly, 2006, 1094 (1) : 3 - 3
[12] UK MHRA pilots UK-wide patient reporting system
Reactions Weekly, 2005, 1075 (1) : 2 - 2
[13] UK MHRA to review prohibition of Kavain, invites submissions
Reactions Weekly, 2005, 1038 (1) : 2 - 2
[14] UK MHRA reports lenalidomide-linked AEs
Reactions Weekly, 2008, 1215 (1) : 3 - 3
[15] Signal detection in the UK: The use of quantitative methods at the MHRA
Ekins-Daukes, S.
Kauser, S.
Wise, L.
DRUG SAFETY, 2007, 30 (10) : 963 - 963
[16] Tacrolimus formulations: UK MHRA issues safety update
Reactions Weekly, 2009, 1236 (1) : 3 - 3
[17] Codeine not to be used for cough in children, says UK MHRA
Reactions Weekly, 2010, 1323 (1) : 5 - 5
[18] UK MHRA recalls contaminated losartan, irbesartan batches
Reactions Weekly, 2021, 1863 (1) : 6 - 6
[19] UK MHRA reiterates concerns regarding Chinese medicines
Reactions Weekly, 2004, 1018 (1) : 2 - 2
[20] UK MHRA warns against Chinese slimming aids
Reactions Weekly, 2005, 1070 (1) : 2 - 2

← 1 2 3 4 5 →